Scott Dunseth Myers - Net Worth and Insider Trading

Scott Dunseth Myers Net Worth

The estimated net worth of Scott Dunseth Myers is at least $6 Million dollars as of 2024-11-13. Scott Dunseth Myers is the CEO of Viridian Therapeutics Inc and owns about 259,500 shares of Viridian Therapeutics Inc (VRDN) stock worth over $6 Million. Scott Dunseth Myers is also the President and CEO of Cascadian Therapeutics Inc and owns about 49,716 shares of Cascadian Therapeutics Inc (CASC) stock worth over $498,154. Details can be seen in Scott Dunseth Myers's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Scott Dunseth Myers has not made any transactions after 2023-04-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Scott Dunseth Myers

Scott Dunseth Myers Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Scott Dunseth Myers owns 6 companies in total, including Cartesian Therapeutics Inc (RNAC) , Harpoon Therapeutics Inc (HARP) , and AMAG Pharmaceuticals Inc (AMAG) among others .

Click here to see the complete history of Scott Dunseth Myers’s form 4 insider trades.

Insider Ownership Summary of Scott Dunseth Myers

Ticker	Comapny	Transaction Date	Type of Owner
RNAC	Cartesian Therapeutics Inc	2019-12-23	director
HARP	Harpoon Therapeutics Inc	2019-02-07	director
AMAG	AMAG Pharmaceuticals Inc	2020-04-28	director & President & CEO
		2018-03-09	director & President and CEO
		2021-10-19	director
		2023-04-12	director & Chief Executive Officer

Scott Dunseth Myers Latest Holdings Summary

Scott Dunseth Myers currently owns a total of 2 stocks. Among these stocks, Scott Dunseth Myers owns 259,500 shares of Viridian Therapeutics Inc (VRDN) as of April 12, 2023, with a value of $6 Million and a weighting of 92.12%. Scott Dunseth Myers also owns 49,716 shares of Cascadian Therapeutics Inc (CASC) as of August 11, 2017, with a value of $498,154 and a weighting of 7.88%.

Latest Holdings of Scott Dunseth Myers

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
VRDN	Viridian Therapeutics Inc	2023-04-12	259,500	22.44	5,823,180
CASC	Cascadian Therapeutics Inc	2017-08-11	49,716	10.02	498,154

Holding Weightings of Scott Dunseth Myers

Scott Dunseth Myers Form 4 Trading Tracker

According to the SEC Form 4 filings, Scott Dunseth Myers has made a total of 2 transactions in Viridian Therapeutics Inc (VRDN) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Viridian Therapeutics Inc is the acquisition of 4,000 shares on April 12, 2023, which cost Scott Dunseth Myers around $101,480.

According to the SEC Form 4 filings, Scott Dunseth Myers has made a total of 0 transactions in Cascadian Therapeutics Inc (CASC) over the past 5 years. The most-recent trade in Cascadian Therapeutics Inc is the acquisition of 5,500 shares on August 11, 2017, which cost Scott Dunseth Myers around $20,570.

Insider Trading History of Scott Dunseth Myers

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Scott Dunseth Myers Trading Performance

GuruFocus tracks the stock performance after each of Scott Dunseth Myers's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Scott Dunseth Myers is 5.56%. GuruFocus also compares Scott Dunseth Myers's trading performance to market benchmark return within the same time period. The performance of stocks bought by Scott Dunseth Myers within 3 months outperforms 3 times out of 8 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Scott Dunseth Myers's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Scott Dunseth Myers

Average Return

Average return per transaction

Outperforming Transactions

2 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	1.63
Relative Return to S&P 500(%)	-0.6

Scott Dunseth Myers Ownership Network

Ownership Network List of Scott Dunseth Myers

No Data

Ownership Network Relation of Scott Dunseth Myers

Scott Dunseth Myers Owned Company Details

What does Cartesian Therapeutics Inc do?

Who are the key executives at Cartesian Therapeutics Inc?

Scott Dunseth Myers is the director of Cartesian Therapeutics Inc. Other key executives at Cartesian Therapeutics Inc include Chief Medical Officer Peter G Traber , director & President & CEO Carsten Brunn , and Chief Scientific Officer Takashi Kei Kishimoto .

Cartesian Therapeutics Inc (RNAC) Insider Trades Summary

Over the past 18 months, Scott Dunseth Myers made no insider transaction in Cartesian Therapeutics Inc (RNAC). Other recent insider transactions involving Cartesian Therapeutics Inc (RNAC) include a net purchase of 1,437,053 shares made by Timothy A Springer , a net purchase of 7,500 shares made by Timothy C Barabe , and a net sale of 2,932 shares made by Carsten Brunn .

In summary, during the past 3 months, insiders sold 0 shares of Cartesian Therapeutics Inc (RNAC) in total and bought 205,721 shares, with a net purchase of 205,721 shares. During the past 18 months, 121 shares of Cartesian Therapeutics Inc (RNAC) were sold and 262,014 shares were bought by its insiders, resulting in a net purchase of 261,893 shares.

Cartesian Therapeutics Inc (RNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cartesian Therapeutics Inc Insider Transactions

No Available Data

What does Harpoon Therapeutics Inc do?

Who are the key executives at Harpoon Therapeutics Inc?

Scott Dunseth Myers is the director of Harpoon Therapeutics Inc. Other key executives at Harpoon Therapeutics Inc include 10 percent owner Vijay K Lathi , Chief Medical Officer Luke Nathaniel Walker , and Principal Fin. & Acctng Ofc. Frank J Lanza .

Harpoon Therapeutics Inc (HARP) Insider Trades Summary

Over the past 18 months, Scott Dunseth Myers made no insider transaction in Harpoon Therapeutics Inc (HARP). Other recent insider transactions involving Harpoon Therapeutics Inc (HARP) include a net purchase of 21,397,205 shares made by Merck & Co., Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Harpoon Therapeutics Inc (HARP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Harpoon Therapeutics Inc (HARP) were sold and 21,397,205 shares were bought by its insiders, resulting in a net purchase of 21,397,205 shares.

Harpoon Therapeutics Inc (HARP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Harpoon Therapeutics Inc Insider Transactions

No Available Data

What does AMAG Pharmaceuticals Inc do?

Who are the key executives at AMAG Pharmaceuticals Inc?

Scott Dunseth Myers is the director & President & CEO of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Lp , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Cascadian Therapeutics Inc do?

Who are the key executives at Cascadian Therapeutics Inc?

Scott Dunseth Myers is the director & President and CEO of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea Partners 15, L.p. , 10 percent owner Florence Anthony A. Jr. , and 10 percent owner Peter W. Sonsini .

Cascadian Therapeutics Inc (CASC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cascadian Therapeutics Inc Insider Transactions

No Available Data

What does Dynavax Technologies Corp do?

Who are the key executives at Dynavax Technologies Corp?

Scott Dunseth Myers is the director of Dynavax Technologies Corp. Other key executives at Dynavax Technologies Corp include Principal Accounting Officer Justin Burgess , Chief Medical Officer and VP Robert Janssen , and Senior Vice President David F Novack .

Dynavax Technologies Corp (DVAX) Insider Trades Summary

Over the past 18 months, Scott Dunseth Myers made no insider transaction in Dynavax Technologies Corp (DVAX). Other recent insider transactions involving Dynavax Technologies Corp (DVAX) include a net sale of 169,000 shares made by David F Novack , a net sale of 46,327 shares made by Robert Janssen , and a net sale of 3,000,000 shares made by Hack Andrew A. F. .

In summary, during the past 3 months, insiders sold 0 shares of Dynavax Technologies Corp (DVAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,247,529 shares of Dynavax Technologies Corp (DVAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,247,529 shares.

Dynavax Technologies Corp (DVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dynavax Technologies Corp Insider Transactions

No Available Data

What does Viridian Therapeutics Inc do?

Who are the key executives at Viridian Therapeutics Inc?

Scott Dunseth Myers is the director & Chief Executive Officer of Viridian Therapeutics Inc. Other key executives at Viridian Therapeutics Inc include director & President and CEO Stephen F. Mahoney , Chief Operating Officer Thomas W. Beetham , and director & other: See Remarks Fairmount Healthcare Fund Ii Gp Llc .

Viridian Therapeutics Inc (VRDN) Insider Trades Summary

Over the past 18 months, Scott Dunseth Myers made no insider transaction in Viridian Therapeutics Inc (VRDN). Other recent insider transactions involving Viridian Therapeutics Inc (VRDN) include a net sale of 9,796 shares made by Lara Meisner , a net purchase of 1,600,000 shares made by Fairmount Healthcare Fund Ii Gp Llc , and a net purchase of 476,190 shares made by Fairmount Healthcare Fund Gp Llc .

In summary, during the past 3 months, insiders sold 0 shares of Viridian Therapeutics Inc (VRDN) in total and bought 1,626,400 shares, with a net purchase of 1,626,400 shares. During the past 18 months, 9,796 shares of Viridian Therapeutics Inc (VRDN) were sold and 2,102,590 shares were bought by its insiders, resulting in a net purchase of 2,092,794 shares.

Viridian Therapeutics Inc (VRDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viridian Therapeutics Inc Insider Transactions

No Available Data

Scott Dunseth Myers Mailing Address

Above is the net worth, insider trading, and ownership report for Scott Dunseth Myers. You might contact Scott Dunseth Myers via mailing address: C/o Cascadian Therapeutics, Inc., 3101 Western Ave., Suite 600, Seattle Wa 98121.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.